中华耳鼻咽喉头颈外科杂志
中華耳鼻嚥喉頭頸外科雜誌
중화이비인후두경외과잡지
CHINESE JOURNAL OF OTORHINOLARYNGOLOGY HEAD AND NECK SURGERY
2012年
8期
638-641
,共4页
李钦%李玉芬%陈彦林%张大良%刘言训
李欽%李玉芬%陳彥林%張大良%劉言訓
리흠%리옥분%진언림%장대량%류언훈
鼻炎,变应性,常年性%疾病模型,动物%白细胞介素5受体α亚单位%白细胞介素13受体α2亚单位%血管细胞黏附分子-1%干扰素Ⅱ型
鼻炎,變應性,常年性%疾病模型,動物%白細胞介素5受體α亞單位%白細胞介素13受體α2亞單位%血管細胞黏附分子-1%榦擾素Ⅱ型
비염,변응성,상년성%질병모형,동물%백세포개소5수체α아단위%백세포개소13수체α2아단위%혈관세포점부분자-1%간우소Ⅱ형
Rhinitis,allergic,perennial%Disease models,animal%Interleukin-5 receptor alpha subunit%Interleukin-13 receptor alpha 2 subunit%Vascular cell adhesion molecule-1%Interferon type Ⅱ
目的 探讨鼻腔联合应用可溶性白细胞介素5受体α( soluble interleukin 5 receptor alpha,sIL-5 Rα)及sIL-13Rα2对变应性鼻炎(allergic rhinitis,AR)大鼠血管细胞黏附分子1(vascular cell adhesion molecule 1,VCAM-1)和γ干扰素(interferon gamma,IFN-γ)水平的影响.方法 将Wistar大鼠50只以随机数字表法随机分为A组(对照组)、B组(AR组)、C组(sIL-5Rα治疗组)、D组(sIL-13Rα2治疗组)及E组(sIL-5Rα联合sIL-13Rα2治疗组,简称联合治疗组).AR组及各治疗组用卵清蛋白( ovalbumin,OVA)和氢氧化铝致敏,用OVA激发,建立大鼠AR模型,对照组用生理盐水代替.其中sIL-5Rα治疗组、sIL-13Rα2治疗组及联合治疗组在第31 ~ 38天,于激发前30 min每只大鼠每日每侧鼻腔分别滴入100 μg sIL-5Rα、100 μg sIL-13Rα2、sIL-5 Rα及sIL-13Rα2各100 μg,AR组则于激发前30 min滴入磷酸盐缓冲液50μl.比较各组大鼠血清及鼻腔灌洗液中VCAM-1、IFN-γ水平的变化.以SPSS 17.0软件进行统计学分析.结果 B组血清及鼻腔灌洗液中VCAM-1含量较A组明显升高(P值均<0.01),而IFN-γ含量明显降低(P值均<0.01);C、D、E组血清及鼻腔灌洗液中VCAM-1含量较B组明显降低(P值均<0.01),而IFN-γ的含量明显升高(P值均<0.01);E组血清及鼻腔灌洗液中VCAM-1含量[分别为(283.5±5.7) μg/L、(101.8±4.8)μg/L]分别较C[分别为(311.5±12.6) μg/L、(133.9±5.8) μg/L]、D组[分别为(304.7±6.6) μg/L、(128.5±7.7) μg/L]明显降低(P值均<0.01),而IFN-γ的含量[E组分别为(874.7±9.6)、(349.2±12.1) pg/ml;C组分别为(600.2±16.1)、(195.5±16.1)pg/ml;D组分别为(577.9±9.6)、(196.7±9.9) pg/ml]明显升高(P值均<0.01).结论 联合应用sIL-5Rα及sIL-13 Rα2治疗大鼠AR,可明显降低血清及鼻腔灌洗液中VCAM-1含量,同时升高IFN-γ含量,从而达到缓解和治疗AR的目的.
目的 探討鼻腔聯閤應用可溶性白細胞介素5受體α( soluble interleukin 5 receptor alpha,sIL-5 Rα)及sIL-13Rα2對變應性鼻炎(allergic rhinitis,AR)大鼠血管細胞黏附分子1(vascular cell adhesion molecule 1,VCAM-1)和γ榦擾素(interferon gamma,IFN-γ)水平的影響.方法 將Wistar大鼠50隻以隨機數字錶法隨機分為A組(對照組)、B組(AR組)、C組(sIL-5Rα治療組)、D組(sIL-13Rα2治療組)及E組(sIL-5Rα聯閤sIL-13Rα2治療組,簡稱聯閤治療組).AR組及各治療組用卵清蛋白( ovalbumin,OVA)和氫氧化鋁緻敏,用OVA激髮,建立大鼠AR模型,對照組用生理鹽水代替.其中sIL-5Rα治療組、sIL-13Rα2治療組及聯閤治療組在第31 ~ 38天,于激髮前30 min每隻大鼠每日每側鼻腔分彆滴入100 μg sIL-5Rα、100 μg sIL-13Rα2、sIL-5 Rα及sIL-13Rα2各100 μg,AR組則于激髮前30 min滴入燐痠鹽緩遲液50μl.比較各組大鼠血清及鼻腔灌洗液中VCAM-1、IFN-γ水平的變化.以SPSS 17.0軟件進行統計學分析.結果 B組血清及鼻腔灌洗液中VCAM-1含量較A組明顯升高(P值均<0.01),而IFN-γ含量明顯降低(P值均<0.01);C、D、E組血清及鼻腔灌洗液中VCAM-1含量較B組明顯降低(P值均<0.01),而IFN-γ的含量明顯升高(P值均<0.01);E組血清及鼻腔灌洗液中VCAM-1含量[分彆為(283.5±5.7) μg/L、(101.8±4.8)μg/L]分彆較C[分彆為(311.5±12.6) μg/L、(133.9±5.8) μg/L]、D組[分彆為(304.7±6.6) μg/L、(128.5±7.7) μg/L]明顯降低(P值均<0.01),而IFN-γ的含量[E組分彆為(874.7±9.6)、(349.2±12.1) pg/ml;C組分彆為(600.2±16.1)、(195.5±16.1)pg/ml;D組分彆為(577.9±9.6)、(196.7±9.9) pg/ml]明顯升高(P值均<0.01).結論 聯閤應用sIL-5Rα及sIL-13 Rα2治療大鼠AR,可明顯降低血清及鼻腔灌洗液中VCAM-1含量,同時升高IFN-γ含量,從而達到緩解和治療AR的目的.
목적 탐토비강연합응용가용성백세포개소5수체α( soluble interleukin 5 receptor alpha,sIL-5 Rα)급sIL-13Rα2대변응성비염(allergic rhinitis,AR)대서혈관세포점부분자1(vascular cell adhesion molecule 1,VCAM-1)화γ간우소(interferon gamma,IFN-γ)수평적영향.방법 장Wistar대서50지이수궤수자표법수궤분위A조(대조조)、B조(AR조)、C조(sIL-5Rα치료조)、D조(sIL-13Rα2치료조)급E조(sIL-5Rα연합sIL-13Rα2치료조,간칭연합치료조).AR조급각치료조용란청단백( ovalbumin,OVA)화경양화려치민,용OVA격발,건립대서AR모형,대조조용생리염수대체.기중sIL-5Rα치료조、sIL-13Rα2치료조급연합치료조재제31 ~ 38천,우격발전30 min매지대서매일매측비강분별적입100 μg sIL-5Rα、100 μg sIL-13Rα2、sIL-5 Rα급sIL-13Rα2각100 μg,AR조칙우격발전30 min적입린산염완충액50μl.비교각조대서혈청급비강관세액중VCAM-1、IFN-γ수평적변화.이SPSS 17.0연건진행통계학분석.결과 B조혈청급비강관세액중VCAM-1함량교A조명현승고(P치균<0.01),이IFN-γ함량명현강저(P치균<0.01);C、D、E조혈청급비강관세액중VCAM-1함량교B조명현강저(P치균<0.01),이IFN-γ적함량명현승고(P치균<0.01);E조혈청급비강관세액중VCAM-1함량[분별위(283.5±5.7) μg/L、(101.8±4.8)μg/L]분별교C[분별위(311.5±12.6) μg/L、(133.9±5.8) μg/L]、D조[분별위(304.7±6.6) μg/L、(128.5±7.7) μg/L]명현강저(P치균<0.01),이IFN-γ적함량[E조분별위(874.7±9.6)、(349.2±12.1) pg/ml;C조분별위(600.2±16.1)、(195.5±16.1)pg/ml;D조분별위(577.9±9.6)、(196.7±9.9) pg/ml]명현승고(P치균<0.01).결론 연합응용sIL-5Rα급sIL-13 Rα2치료대서AR,가명현강저혈청급비강관세액중VCAM-1함량,동시승고IFN-γ함량,종이체도완해화치료AR적목적.
Objective To investigate the effects of sIL-5Rα and sIL-13Rα2 on VCAM-1 and IFN-γ in allergic rhinitis rats.Methods A total of 50 Wistar rats were randomly divided into 5 groups:the normal group(group A),the allergic rhinitis model group (group B),the sIL-5Rα treatment group( group C),the sIL-13Roα2 treatment group( group D),the combination of sIL-5Rα and sIL-13Rα2 treatment group( group E or the combined treatment group).Rats in the latter 4 groups were sensitized with ovalbumin ( OVA ) and Al(OH)3,and challenged with OVA to establish allergic rhinitis models,while rats in the normal group were treated with saline.Rats in the sIL-5Rα treatment group,the sIL-13 Rα2 treatment group and the combined treatment group were absorbed on day 31 to day 38 once daily once nasal cavity with sIL-5Rα( 100 μg),sIL-13Rα2 ( 100 μg) and the combination of sIL-5Rα ( 100 μg) and sIL-13Rα2 ( 100 μg) 30 min before challenged,while rats in the allergic rhinitis model group received PBS( 50 μl ).Then the levels of VCAM-1 and IFN-γ in serum and nasal lavage fluid(NLF) were measured by ELISA.Results Compared with the normal group,the levels of VCAM-1 in the allergic rhinitis model group were higher,while IFN-γ were lower (all P <0.01 ).Compared with the allergic rhinitis model group,the sIL-5Rα treatment group,the sIL-13Rα2 treatment group and the combined treatment group could effectively reduced serum and NLF VCAM-1 level [ group E:(283.5 ±5.7) μg/L,(101.8 ±4.8) μg/L; group C:(311.5 ± 12.6) μg/L,( 133.9 ±5.8) μg/L; group D:(304.7 ±6.6) μg/L,( 128.5 ±7.7) μg/L],and increased IFN-γ level [ group E:(874.7 ±9.6) pg/ml,(349.2 ± 12.1 ) pg/ml; group C:(600.2 ± 16.1 ) pg/ml,( 195.5 ± 16.1 ) pg/ml; group D:(577.9 ± 9.6) pg/ml,( 196.7 ± 9.9) pg/ml ]; compared with single treatment,the combined treatment group also had significant differences (P < 0.01 ).Conclusions Combined treatment with sIL-5Rα and sIL-13Rα2 to treat the allergic rhinitis rats can significantly reduce VCAM-1 levels in serum and NLF,and increase IFN-γ levels,thus,to achieve the purpose of mitigation and treatment of allergic rhinitis.